Higher cumulative dose, 6days/week vs standard, 5days/week moderately hypofractionated palliative radiotherapy with concurrent chemotherapy in locally advanced head and neck carcinoma.
- Registration Number
- CTRI/2023/10/058621
- Lead Sponsor
- AIIMS, New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Treatment naive, Histo-pathologically proven Squamous Cell Carcinoma of head and neck region excluding nasopharyngeal, para-nasal sinus and salivary gland primary
-Defined as incurable or palliative intent by Head and Neck multidisciplinary team (MDT)
-Adequate organ functions and bone marrow reserve
-Eastern Co-operative Oncology Group Performance Score (ECOG PS)- (0-3)
-Age: 18- 70 years
-Negative viral serology markers (HIV, HBsAg, HCV)
-Giving written Informed consent
-Nasopharyngeal, para-nasal sinus or salivary gland primary
-Recurrent disease
-Metastatic disease
-Patients who have previously received oncologic treatment with surgery, radiotherapy or chemotherapy
-Pregnant patients
-Synchronous malignancy or any other malignancy with in last 5 years
-Known uncontrolled medical comorbidities which could impact QOL
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method